Compound being developed to treat the core symptoms of autism

Cellceutix Autism Research Demonstrates Increase In Serotonin Levels In Three Areas Of The Brain

Main Category: Autism
Also Included In: Neurology / Neuroscience
Article Date: 24 Jun 2010 - 4:00 PDT

Cellceutix Corporation (OTCBB: CTIX) is pleased to announce that they have completed another study in the research of KM-391, their novel compound being developed to treat the core symptoms of Autism. Cellceutix is pioneering research in autism treatments and has been making solid progress with pre-clinical research as announced in previous press releases.